tbuckley/cabot-search huggingface dataset:
THU0502 Assessment of severity of atherosclerotic lesions of carotid arteries in men with coronary heart disease depending on bone mineral density and risk of osteoporotic fractures
Authors: T. Raskina, A. Voronkina, M. Letaeva, A. Kokov, O. Barbarash, E. Maluta
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> To assess severity of atherosclerotic lesions of carotid arteries (CA) in men with coronary heart disease (CHD) depending on bone mineral density (BMD) and risk of osteoporotic fractures according to FRAX scale. <h3>Methods</h3> The study involved 102 men aged 51–75 years (median age of 61<sup>55; 65</sup> with CHD, verified by coronary angiography method. All patients underwent dual energy X-ray absorptiometry of lumbar vertebral bodies LI-LIV and femoral neck and colour duplex scanning of extracranial arteries. Assessment of severity of carotid atherosclerosis was carried out by presence of atherosclerotic plaques (ASP) and stenosis of CA, thickness of intima-media (TIM) CA. Threshold TIM for men over age of 50 was considered 0.9 mm (recommendations of American Society of Echocardiography, 2008 Based on results of densitometry value of T-criterion (recommendations ISCD, 2007 men were divided into three groups: 33 patients with osteoporosis (OP, T-criterion ≤2.5), 48 patients with osteopenia (OPE, T–criterion of −1 to −2.5) and 21 men with normal BMD (NBMD, T-criterion ≥–1). On the basis of information on the presence of clinical risk factors of osteoporotic fractures and densitometry data at all included in the study patients FRAX calculator was used to quantify probability of major osteoporotic fractures and hip fracture in next 10 years. <h3>Results</h3> It was found that 86.3% of patients value TIM exceeds threshold value (0.9 mm). Thickening of intima-media complex was in men with OP in 88.0% of cases, with OPE – in 87.5%, with NBMD – in 81.0% without statistically significant differences (p&gt;0.05). In a comparative analysis of atherosclerotic lesions CA found that men with OP significantly were more likely to have ASP in CA (75.8%) compared to patients with OPE (43.7%, p=0.010) and NBMD (38.1%, p=0.016). Stenosis of CA in all investigated men was discovered in 54 cases (53%). Comparative analysis showed that in patients with OP percentage of patients with stenosis of CA was 2 times more than men with NBMD (75.8% vs 38.1%, p=0.006) and was significantly higher than proportion of such patients in the group with OPE (44.0%, p=0.004). In all included the study patients 10 year absolute risk of major osteoporotic fracture by FRAX was equal to 9.88±7.22, risk of hip fracture – 3.97±6.27. There was inverse correlation of TIM with T–criterion (r=–0.21, p=0.035) and with BMD (r=−0.20, p=0.045) at level of hip and reliable direct correlation between TIM and risk of hip fracture by FRAX (r=0.21, p=0.035). <h3>Conclusions</h3> In men with CHD aged over 50 years low BMD (T–criterion is less than 2.5) is associated with more severe carotid atherosclerosis, and thickening of intima-media CA - with an increased risk of hip fracture. <h3>Disclosure of Interest</h3> None declared
Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes
Authors: Seon Gu Lee, Hee Jung Lee, Moon Soo Yoon, Dong Hyun Kim
Journal: JAMA Dermatology (2019)

Recent studies suggest that dipeptidyl peptidase 4 (DPP-4) inhibitors are associated with an increased risk of developing bullous pemphigoid (BP). Population-based studies on the association between DPP-4 inhibitors and BP are limited.To characterize the potential association between the use of DPP-4 inhibitors and an increased risk of developing BP.This retrospective, nationwide, population-based, case-control study using Korean insurance claims data from January 1, 2012, to December 31, 2016, included patients with newly diagnosed BP and diabetes. Control patients with diabetes (and without BP) were randomly obtained after matching for age, sex, and year of diagnosis within the same period.The number of patients with newly diagnosed BP and diabetes per year and annual changes in the proportion of patients with diabetes among all patients with BP were measured. The association between use of DPP-4 inhibitors and risk of developing BP was analyzed using univariate and multivariate logistic regression analyses.The study included 670 case patients (with diabetes and BP) and 670 control patients (with only diabetes) (mean [SD] age, 75.3 [10.0] years in each group; 342 [51.0%] male in each group). The number of patients with diabetes and BP more than doubled during the study period (from 77 in 2012 to 206 in 2016). The proportion of patients with diabetes among all patients with BP also increased (from 0.18 in 2012 to 0.33 in 2016). The use of DPP-4 inhibitors was associated with a significant increase in the risk of developing BP (adjusted odds ratio [aOR], 1.58; 95% CI, 1.25-2.00; P < .001); among all DPP-4 inhibitors used in Korea, the highest aOR was associated with the use of vildagliptin (aOR, 1.81; 95% CI, 1.31-2.50; P < .001). Subgroup analyses revealed a significant association in male patients (aOR, 1.91; 95% CI, 1.39-2.63; P < .001) and that vildagliptin was the most high-risk DPP-4 inhibitor (aOR, 2.70; 95% CI, 1.73-4.34; P < .001).The findings suggest that DPP-4 inhibitors are associated with a significantly increased risk of the development of BP in patients with diabetes. Of the DPP-4 inhibitors available in Korea, vildagliptin was associated with the highest risk, particularly in male patients. Practitioners should consider that DPP-4 inhibitors, particularly vildagliptin, may be associated with the development of BP in patients with diabetes. These nationwide, population-based results may serve as a foundation for further studies seeking to understand how DPP-4 inhibitors contribute to the development of BP.
FRI0593 Mantoux test is inadequate to define all subjects with latent tubercular infection
Authors: S. Arya, S. Kumar, A. Nath, P. Kapoor, A. Aggarwal, R. Misra, S. Sinha
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Latent TB infection (LTBI), defined as 'a state of persistent immune response to <i>Mycobacterium tuberculosis</i> without clinically-manifested disease', inflicts a third of the world's population and nearly 10% of LTBI positive persons develop TB within 2–5 years. The tuberculin skin test (TST) and, more recently, interferon gamma release assays (IGRAs) are most commonly used for detection of LTBI. However, in a high TB burden setting such as India, both the assays have been found to grossly underestimate the true prevalence of LTBI, since almost equal number of new TB cases emerged from the test-positive and test-negative groups during the follow-up<sup>1</sup>. <h3>Objectives</h3> This study was aimed at exploring whether an <i>in vitro</i> CD3 +T cell response to PPD can complement the <i>in vivo</i> TST response for the determination of true prevalence of LTBI in healthy Indians. <h3>Methods</h3> In this ongoing study, 80 apparently healthy workers (age 19–61 years) at SGPGIMS have been recruited. Their demographic data, including BCG vaccination status and duration of contact with TB patients, was recorded. TST was performed with 5 TU of PPD. Blood T cell (CD3+) responses to PHA (a mitogen, used as positive control) and PPD were determined by flow cytometry in terms of expression of the proliferation-induced nuclear protein Ki67. <h3>Results</h3> 48% of the study subjects showed positivity for TST (skin induration ≥10 mm) and the size of reaction could be correlated with age. There was no association between BCG vaccination status and TST positivity. 72% of the TST positive and 62% of TST negative persons showed positivity for CD3 +T cell response to PPD. Positivity for either assay was found to be 82%. <h3>Conclusions</h3> By combining TST with CD3 +T cell responses, the positivity for PPD was enhanced from 48% (TST alone) to 82%. Therefore, both the assays could be considered as complementary. It remains to be seen whether these assays, either singly or jointly, show a correlation with the emergence of TB in our study population during the follow-up. <h3>Reference</h3> [1] Sharma SK, Vashishtha R, Chauhan LS, Sreenivas V, Seth D. Comparison of TST and IGRA in Diagnosis of Latent Tuberculosis Infection in a High TB-Burden Setting. PLoS ONE2017;12(1):e0169539. <h3>Disclosure of Interest</h3> None declared
Donor Lymphocyte Infusions for the Treatment of Relapsed Non-Hodgkin Lymphoma Following Allogeneic Stem Cell Transplantation: A LWP-EBMT Study
Authors: Stephen Robinson, Ariane Boumendil, Hervé Finel, Irma Khvedelidze, Edward Kanfer, Karl Peggs, Sabine Furst, Ron Ram, Waf Marijt, Elisabeth Vandenberghe, Boris Afanasiev, Gerald Wulf, Yves Chalandon, Johan Maertens, Anna Tsoulkani, Michel Schaap, Dietrich W. Beelen, Gunhan Gurman, Jürgen Finke, Sebastian Wittnebel, Paolo Di Bartolomeo, Johanna Tischer, Paolo Corradini, Dolores Caballero, Maria A V Marzolini, Claire Burney, Giorgio La Nasa, Victoria Potter, Jörg Thomas Bittenbring, Nathalie Fegueux, Nicolaus Kroeger, Norbert Schmitz, Peter Dreger, Silvia Montoto
Journal: Blood (2018)
AB0370 Low serum igf1 is associated with higher cardiovascular risk in the middle-aged women with rheumatoid arthritis independently of the disease related parameters
Authors: M.C. Erlandsson, S.T. Silfverswärd, M. Nadali, R. Pullerits, M.I. Bokarewa
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> To analyse the relation between serum levels of IGF1 and cardiovascular risk (CVR) in women with rheumatoid arthritis (RA). <h3>Methods</h3> The risk of dying of CV disease within 5 years was calculated using the strategy proposed by Pocock et al. BMJ 2001 in 185 women with RA (mean age 51.7 years) with no previous history of CV events. The CVR and characteristics related to it were analysed with respect to serum IGF1. IGF1 levels below the median of the total cohort were considered low. <h3>Results</h3> The RA women with low IGF1 (n=91, mean 104 pg/ml) had significantly higher CVR compared to those with normal IGF1 (n=94, mean 194 pg/ml) with the predicted risk of 0.51% and 0.17%, respectively (p&gt;10–5). Among the traditional CVR factors, the low IGF1 group was 10 years older (mean 56.8 vs. 46.9 y, p=10–5), lower in height (165 vs. 168 cm, p=0.013, 21% of the patients being &lt;160 cm) and had high prevalence of hypertension (24% vs. 8.5%, p=0.004), while current smoking was similar between the groups (15% vs. 14%). The low IGF1 group displayed the unfavourable metabolic profile with higher BMI (p=0.002) and obesity in 22%, higher predicted body fat content (mean 39.5 vs. 35%, p=10–5), and higher total and LDL cholesterol (p=0.0014 and p=0.0053, respectively). The levels of adiponectin (p=0.032) and HDL-cholesterol (p=0.25) tended to be higher in the low IGF1 group, which resulted in the comparable total cholesterol to HDL ratio between the groups. This could also explain that the prevalence of diabetes mellitus and metabolic syndrome were low. With exception of the disease duration, the groups displayed no significant difference in the RA-related CVR factors such as the disease activity measured by DAS28 (3.29 vs 2.99), systemic inflammation measured by serum IL6 (mean 8.46 vs. 5.99 pg/ml) and IL1β (mean 19.47 vs. 23.1 ng/ml), and the prevalence of seropositivity (91% vs. 92%). The prevalence of treatment with MTX monotherapy was higher in the low IGF1 group (56% vs. 39%, p=0.024), while the use of TNF-inhibitors and other biologic and synthetic anti-rheumatic drugs was similar within the groups. <h3>Conclusions</h3> Serum IGF1 levels in the normal low range are associated with higher CVR in RA female patients. This increase in CVR seems to be independent of the RA-related characteristics. The combination of low height and hypertension argues for the important role of congenital factors in defining serum IGF1 levels in the studied RA women. <h3>Reference</h3> [1] Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ2001;323:75–81. <h3>Disclosure of Interest</h3> None declared
Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial
Authors: Abdulraheem Yacoub, John Mascarenhas, Heidi Elizabeth Kosiorek, Josef T. Prchal, Dmitriy Berenzon, Maria R. Baer, Ellen K Ritchie, Richard T Silver, Craig M. Kessler, Elliott F. Winton, Maria Chiara Finazzi, Alessandro Rambaldi, Alessandro M. Vannucchi, David S. Leibowitz, Damiano Rondelli, Murat O. Arcasoy, Rosalind Catchatourian, Joseph Vadakara, Vittorio Rosti, Elizabeth Hexner, Marina Kremyanskaya, Alicia Orellana, Lonette Sandy, Joseph Tripodi, Vesna Najfeld, Mohamed E. Salama, Rona Singer Weinberg, Raajit K. Rampal, Ruben A Mesa, Judith D Goldberg, Amylou C. Dueck, Ronald Hoffman
Journal: Blood (2017)
AB1397-HPR Reliability, validity and cross-cultural validity of the turkish version of the abilhand questionnaire in rheumatoid arthritis individuals, based on rasch analysis
Authors: B Basakci Calik, E. Gür Kabul, M. Tasci, S. Erel, I.E. Simsek, P. Demir, V. Cobankara
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> 80%–90% of Rheumatoid Arthritis (RA) individuals are thought to be affected by the hands and wrists. Patients complain of various symptoms that cause more difficulty while performing daily activities such as joint pain and stiffness, loss of joint range of motion, reduction of grip strength. Abilhand is a Rasch-built questionnaire and evaluates manual ability. <h3>Objectives</h3> This study aimed to evaluate reliability, validity and the cross-cultural validity of the Turkish version of the Abilhand questionnaire for Rheumatoid Arthritis individuals, based on Rasch Analysis. <h3>Methods</h3> A total of 90 participants who were diagnosed as RA according to the American College of Rheumatology (ACR) 2010 criteria with a mean age of 51.8±10.9 years were included in the study. Manual ability was evaluated by use of Abilhand Questionnaire; disease activity by Disease Activity Score 28 (DAS28), upper limb impairment by Jamar dynamometer, pinchmeter, Nine Hole Peg Test (NHPT); disability by Duruöz Hand Index (DHI) and quality of life by Nottingham Health Profile (NHP). Abilhand results were evaluated using Rasch analysis. <h3>Results</h3> The Abilhand-Turkish, consisting of 27 items, provided the invariance of item difficulty hierarchy in general. Item fit statistics, person-item residual corelation matrix and principal component analysis of the residuals was examined and 8 items were removed. As a result of the deletion of 8 items in the questionnaire, it was determined that the remaining 19 items provided Rasch model compatibility and the invariance of item difficulty hierarchy. DAS28, bilateral grip strength, dominant side, NHPT, DHI ve NHP were significantly correlated with the Abilhand measures. <h3>Conclusions</h3> The Abilhand-Turkish in individuals with rheumatoid arthritis is clinically valid and reliable. We recommend using the Abilhand-Turkish in clinical evaluations, in rehabilitation interventions, and in evaluating improvements due to its sensitivity. <h3>References</h3> [1] Maini RN, Feldmann M. Rheumatoid arthritis. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, eds. Oxford Textbook of Rheumatology, 2nd edn. Oxford: Oxford University Press 1998; 983–1036. [2] Hakkinen A, Hannonen P, Hakkinen K. Muscle strength in healthy people and in patients suffering from recent-onset inflammatory arthritis. Br J Rheumatol1995; 34(4): 355–360. [3] Durez P, Fraselle V, Houssiau F, Thonnard JL, Nielens H, Penta M. Validation of the ABILHAND questionnaire as a measure of manual ability in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(8):1098–105. <h3>Disclosure of Interest</h3> None declared
Combinatorial Targeting of Multiple Shared Antigens By Adapter-CAR-T Cells (aCAR-Ts) Allows Target Cell Discrimination and Specific Lysis Based on Differential Expression Profiles
Authors: Christian M. Seitz, Verena Kieble, Clara Illi, Selina Reiter, Stefan Grote, Joerg Mittelstaet, Dominik Lock, Andrew Kaiser, Sabine Schleicher, Rupert Handgretinger, Peter Lang, Patrick Schlegel
Journal: Blood (2018)
Infographic. Sports injury-related hospitalisations in Australian children: incidence, costs and trends
Authors: Reidar P Lystad, Joanne Tran, Kate Curtis, Gary J Browne, Rebecca J Mitchell
Journal: British Journal of Sports Medicine (2019)

Children are encouraged to participate in sports to improve general health and well-being and to prevent illnesses related to obesity and a sedentary lifestyle.1 2 Although the benefits of participation in sporting activities are undisputed, injury is a common adverse outcome.3 4 Despite the increasing recognition of the issue worldwide, there is very limited high-quality population-based data quantifying the burden of sports injuries in children and monitor changes over time. Such data are essential for decision-makers to prioritise and develop policy and for stakeholders and researchers to evaluate the impact of sports injury prevention efforts in the real-world setting.

This is the first study …
2 Step Myeloablative Haploidentical Transplant (HI MA HSCT) in Intermediate and High-Risk Patients-Changing the Timing of the 2 Step Approach
Authors: Dolores Grosso, Onder Alpdogan, Matthew Carabasi, Joanne Filicko-O'Hara, Sameh Gaballa, Margaret Kasner, Thomas R. Klumpp, Ubaldo Martinez-Outschoorn, Neil Palmisiano, William O'Hara, John L Wagner, Pierluigi Porcu, Neal Flomenberg
Journal: Blood (2018)
FRI0505 Validation of the prognostic value of the histopathological classification of anca-associated glomerulonephritis: a meta-analysis
Authors: M. Wester Trejo, E. van Daalen, J. Schoones, O. Dekkers, J. Bruijn, I. Bajema
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> In 2010, a histopathological classification of antineutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis (AAGN) was proposed by an international consortium of renal pathologists and nephrologists. It comprises four biopsy classes: focal, crescentic, mixed and sclerotic, the order of which was shown, in the initial publication, to correspond to increasing severity of renal impairment during follow-up. <h3>Objectives</h3> The aim of this meta-analysis was to evaluate the prognostic value of the phenotypical classes by means of validation studies that have been published since. <h3>Methods</h3> A literature search was performed using Web of Science, Google Scholar, PubMed and Embase in March 2017, selecting studies that associated histopathological class to renal outcome in adult patients with AAGN. The risk of developing end-stage renal disease (ESRD) during follow-up was compared between classes using a meta-analysis with random effects model. Weighted relative risks (RR) with 95% confidence intervals (95% CI) were reported. <h3>Results</h3> Nineteen studies were included with a total of 2408 patients. Using sclerotic class as a reference category, ESDR risk was lower in the crescentic class (RR 0.53, 95% CI 0.43–0.64); RR in focal was lower than in crescentic class (RR 0.27 95% CI 0.20–0.37). RR in crescentic compared to mixed class was 1.18 (95% CI 0.95–1.45); RR in focal compared to mixed class was 0.34 (95% CI 0.25–0.47). <h3>Conclusions</h3> Our meta-analysis shows that the risk for developing ESRD increased with more severe histopathological lesions. We found no difference between the crescentic and mixed classes, pointing towards a comparable risk profile with regard to ESRD. We are currently performing an individual patient data meta-analysis, as this technique is better equipped to deal with study heterogeneity. For the moment, this meta-analysis confirms the use of the histopathological classification system as a predictor of renal outcome in the prognostication of patients with AAGN. <h3>Reference</h3> [1] Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, Neumann I, Noel LH, Pusey CD, Waldherr R, Bruijn JA, Bajema IM. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol2010;21:1628–1636. <h3>Disclosure of Interest</h3> None declared
ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience
Authors: Michele Malagola, Jacopo Peccatori, Raffaella Greco, Francesca Serio, Stella Santarone, Anna Paola Iori, Luisa Quatrocchi, Walter Barbieri, Antonella Abruzzese, Salvatore Leotta, Alessandra Carotti, Antonio Pierini, Benedetta Rambaldi, Enrico Morello, Nicola Polverelli, Alessandro Turra, Federica Cattina, Lisa Gandolfi, Paolo Di Bartolomeo, Giuseppe Milone, Andrea Velardi, Robin Foà, Fabio Ciceri, Domenico Russo
Journal: Blood (2018)
Higher Incidence of Hemorrhagic Cystitis after Haploidentical Compared to Matched Sibling Donor Transplantation
Authors: Srinivasa Reddy Sanikommu, Olivia Copelan, Jiaxian He, Candace M. Butler, Michael R. Grunwald, Nilanjan Ghosh, Jing Ai, Thomas G. Knight, Brittany Ragon, Ryan Jacobs, Bei Hu, Saad Z. Usmani, James T Symanowski, Zainab Shahid
Journal: Blood (2018)
BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study
Authors: Tsila Zuckerman, Ron Ram, Maya Koren-Michowitz, Luiza Akria, Ron Hoffman, Israel Henig, Yishai Ofran, Noa Lavi, Netanel A Horowitz, Olga Nudelman, Shay Yeganeh, Stela Gengrinovitch, Liat Flaishon, Ruth Ben Yakar, Jacob M. Rowe
Journal: Blood (2017)